ArticleScientific reports2026
Thrombin is increased in diabetic retinal pathology in the STZ mice model, and its attenuation by a specific inhibitor, PARIN5, is associated with preserved function.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Protease-activated receptor 1 in diabetes and its chronic complications: signaling mechanisms and emerging therapeutic advances.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Diabetic retinopathy (DR) is a leading cause of vision loss in working-age adults. Retinal neurodegeneration precedes vascular pathology, highlighting the need to identify early molecular biomarkers as a target for intervention. The thrombin receptor, protease-activated receptor-1 (PAR1), a G-protein-coupled receptor involved in coagulation and neuroinflammatory signaling, is expressed in the retina and has been implicated in retinal barrier dysfunction and angiogenesis in late DR. We presently addressed its role in early diabetic neuroretinal pathology. We investigated the thrombin/PAR1 pathway one month after induction of diabetes with streptozotocin (STZ) in mice. Retinal thrombin activity and coagulation-related gene expression were quantified, PAR1 localization was examined by immunofluorescence and cytosolic/nuclear fractionated Western blotting, and retinal function was assessed by electroretinography (ERG). Additionally, we assessed the therapeutic potential of PARIN5, a selective thrombin-PAR1 modulator, across these outcome measures. Diabetic retinas showed increased thrombin activity (2.496 vs. 1.00 mU/ml, p = 0.01) and PAR1 mRNA expression (1.31 ± 0.11 vs. 1.00 ± 0.08, p = 0.028), along with decreased prothrombin and factor X mRNA (0.64 ± 0.07 vs. 1.00 ± 0.05, p = 0.0025; 0.75 ± 0.03 vs. 1.00 ± 0.09, p = 0.042; respectively). Immunofluorescence confirmed increased PAR1 staining, including nuclear localization, confirmed by fractionated Western blotting. PARIN5 treatment reduced thrombin activity (p = 0.0091), attenuated PAR1 staining, and preserved both dark-adapted (ratio post treatment/pre-diabetes induction: maximal a-wave 1.23 ± 0.13 vs. 0.39 ± 0.07 for carrier-treated mice, p = 0.0002; maximal b-wave 1.15 ± 0.14 vs. 0.49 ± 0.08, p = 0.0083) and light-adapted (maximal b-wave 1.21 ± 0.14 vs. 0.51 ± 0.05, p = 0.0024) ERG responses. Importantly, these molecular and functional changes occurred without morphological alterations in the retina. In conclusion, we identify thrombin/PAR1 increase and nuclear translocation as a novel early event in diabetic retinopathy and demonstrate that PARIN5 treatment preserves retinal function before structural pathology emerges. Modulation of thrombin/PAR1 signaling may provide a new therapeutic strategy for halting or delaying the progression of DR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.